DE3883374D1 - Acylatiertes uridin und cytidin und deren verwendungen. - Google Patents
Acylatiertes uridin und cytidin und deren verwendungen.Info
- Publication number
- DE3883374D1 DE3883374D1 DE8888909932T DE3883374T DE3883374D1 DE 3883374 D1 DE3883374 D1 DE 3883374D1 DE 8888909932 T DE8888909932 T DE 8888909932T DE 3883374 T DE3883374 T DE 3883374T DE 3883374 D1 DE3883374 D1 DE 3883374D1
- Authority
- DE
- Germany
- Prior art keywords
- cytidine
- acylated
- uridine
- acylated uridine
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11592987A | 1987-10-28 | 1987-10-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3883374D1 true DE3883374D1 (de) | 1993-09-23 |
DE3883374T2 DE3883374T2 (de) | 1993-12-09 |
Family
ID=22364208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE88909932T Expired - Lifetime DE3883374T2 (de) | 1987-10-28 | 1988-10-27 | Acylatiertes uridin und cytidin und deren verwendungen. |
Country Status (12)
Country | Link |
---|---|
US (1) | US5583117A (de) |
EP (1) | EP0339075B1 (de) |
JP (6) | JP2894610B2 (de) |
AT (1) | ATE93236T1 (de) |
AU (1) | AU2789989A (de) |
CA (1) | CA1321994C (de) |
DE (1) | DE3883374T2 (de) |
HK (1) | HK1005740A1 (de) |
IL (1) | IL88208A (de) |
IN (1) | IN167680B (de) |
WO (1) | WO1989003837A1 (de) |
ZA (1) | ZA89232B (de) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US7776838B1 (en) | 1987-10-28 | 2010-08-17 | Wellstat Therapeutics Corporation | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US6060459A (en) * | 1987-10-28 | 2000-05-09 | Pro-Neuron, Inc. | Enhancing blood cell count with oxypurine nucleosides |
US6329350B1 (en) | 1987-10-28 | 2001-12-11 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
US7173017B1 (en) | 1987-10-28 | 2007-02-06 | Wellstat Therapeutics Corporation | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
US5736531A (en) | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
IT1219667B (it) * | 1988-06-21 | 1990-05-24 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico |
US5216142A (en) * | 1989-04-17 | 1993-06-01 | Efamol Holdings Plc | Anti-virals |
US4964959A (en) * | 1990-04-12 | 1990-10-23 | Olin Hunt Specialty Products Inc. | Process for preparing a nonconductive substrate for electroplating |
IT1241984B (it) * | 1990-06-13 | 1994-02-02 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete |
US5248672A (en) * | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
RU2158269C2 (ru) * | 1991-02-08 | 2000-10-27 | Про-Ньюрон, Инк. | Ацильные производные гуанозина, инозина, ксантозина, дезоксиинозина, дезоксигуанозина, инозин-2',3'-(ациклического)диалкоголя или их фармацевтически приемлемые соли, фармацевтическая композиция, стимулирующая гемопоэз, способ лечения цитопении |
ES2160579T3 (es) * | 1991-07-05 | 2001-11-16 | Pro Neuron Inc | Tratamiento de la toxicidad de un agente quimioterapeutico y un agente antivirico con nucleosidos de pirimidina acilados. |
EP0679160B1 (de) * | 1992-12-08 | 2004-11-17 | Wellstat Therapeutics Corporation | Pyrimidinnukleotid-vorläufer zur behandlung entzündlicher hepatitis |
DK0661051T3 (da) * | 1993-10-11 | 2006-05-22 | Viatris Gmbh | Medikament til behandling af hypertension |
US5641758A (en) * | 1993-11-10 | 1997-06-24 | Kluge; Michael | Cytarabine derivatives, the preparation and use thereof |
WO1996001115A1 (en) * | 1994-07-01 | 1996-01-18 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
US6703394B2 (en) | 1996-02-16 | 2004-03-09 | Medivir Ab | Acyclic nucleoside derivatives |
US5869493A (en) | 1996-02-16 | 1999-02-09 | Medivir Ab | Acyclic nucleoside derivatives |
CA2271135A1 (en) * | 1996-11-12 | 1998-05-22 | Medivir Ab | Nucleosides |
CZ300757B6 (cs) * | 1997-08-15 | 2009-08-05 | Medivir Ab | Nukleosidové analogy, jako jsou antivirální cinidla obsahující inhibitory retrovirální reverzní transkriptázy a DNA polymerázy viru hepatitidy B (HBV) |
US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
ES2294850T3 (es) * | 1998-07-31 | 2008-04-01 | Massachusetts Institute Of Technology | Tratamiento de la enfermedad de alzheimer mediante el aumento de los niveles de citidina in vivo. |
US20060069061A1 (en) * | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
US8314064B2 (en) * | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
US6136339A (en) | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
US7807654B2 (en) * | 1998-08-31 | 2010-10-05 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US7915233B1 (en) | 1998-08-31 | 2011-03-29 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
PT1171137E (pt) * | 1999-02-23 | 2008-03-17 | Univ California | Utilização de triacetiluridina para o tratamento de perturbações mitocondriais |
SE521031C2 (sv) * | 1999-05-05 | 2003-09-23 | Srinivas Uppugunduri | Nya specifika inhibitorer av akut och kronisk inflammation |
ES2425114T3 (es) | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
EA200301204A1 (ru) * | 2001-04-30 | 2004-04-29 | Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель | Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты) |
JP3968347B2 (ja) * | 2001-09-05 | 2007-08-29 | ヤマサ醤油株式会社 | 糖尿病性神経障害用医薬組成物 |
AUPR951101A0 (en) * | 2001-12-13 | 2002-01-24 | Centre For Molecular Biology And Medicine | Method of treatment |
BR0316054A (pt) * | 2002-11-08 | 2005-09-20 | Mclean Hospital Corp | Compostos para tratamento de dependência e privação de tabaco |
CN102552917A (zh) | 2003-08-13 | 2012-07-11 | 比奥孔有限公司 | 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂 |
US20070160554A1 (en) * | 2003-11-03 | 2007-07-12 | Cognis Ip Management Gmbh | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same |
CA2550299C (en) * | 2003-12-22 | 2010-03-30 | Christopher R. Roberts | Process for fluorocytidine derivatives |
US9572830B2 (en) * | 2004-05-13 | 2017-02-21 | Massachusetts Institute Of Technology | Uridine effects on dopamine release |
JP4656859B2 (ja) * | 2004-05-19 | 2011-03-23 | 明治飼糧株式会社 | 酸化ストレス抑制剤 |
EP1784199A4 (de) | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | Verbindungen zur behandlung von marihuana-abhängigkeit, entzug und konsum |
CA2595126A1 (en) * | 2005-01-14 | 2006-07-20 | The Regents Of The University Of California | Methods and compositions for preventing and treating a disease related to glycan dysregulation |
US20070114476A1 (en) * | 2005-11-04 | 2007-05-24 | Williams Christopher P | Low radiocarbon nucleotide and amino acid dietary supplements |
EP2158462A4 (de) | 2007-05-03 | 2010-05-05 | Radiocarb Genetics Inc | Nahrungsergänzungen mit wenig radiokohlenstoff und herstellungsverfahren dafür |
EP2217075A4 (de) | 2007-11-02 | 2012-01-25 | Massachusetts Inst Technology | Uridin-nahrungszusatz-einverständnis-verfahren und verwendung davon |
WO2011133580A1 (en) | 2010-04-19 | 2011-10-27 | Back Bay Scientific Llc | Use of drugs that activate p2y receptors to enhance synaptogenesis |
WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
JP5788715B2 (ja) * | 2011-05-31 | 2015-10-07 | キリンホールディングス株式会社 | 酸素消費量及びエネルギー消費量の低減剤 |
US9331955B2 (en) | 2011-06-29 | 2016-05-03 | Microsoft Technology Licensing, Llc | Transporting operations of arbitrary size over remote direct memory access |
EP2556832B1 (de) * | 2011-08-12 | 2017-07-19 | Universitätsklinikum Freiburg | Uridin und Uridinanaloga zur Behandlung von Chronischer obstruktiver Lungenerkrankung |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
DE202015105351U1 (de) | 2015-10-09 | 2016-01-07 | Apotheke am Schlossplatz Inh. Mario Ganster e.K. | Diätetische Zusammensetzung |
CA3029005A1 (en) * | 2016-06-27 | 2018-01-04 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
CN114469981A (zh) * | 2021-12-16 | 2022-05-13 | 中国科学院动物研究所 | 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3847898A (en) * | 1969-05-27 | 1974-11-12 | Upjohn Co | N4-trihaloethoxy carbonyl arabino-furanosyl cytosine 5'-esters |
US3585188A (en) * | 1969-06-16 | 1971-06-15 | Takeda Chemical Industries Ltd | Process for producing 2'-deoxyuridine |
GB1297398A (de) * | 1969-08-06 | 1972-11-22 | ||
US3894000A (en) * | 1971-01-27 | 1975-07-08 | Upjohn Co | Ara-cytidine derivatives and process of preparation |
US3868451A (en) * | 1971-03-30 | 1975-02-25 | Abbott Lab | Adenosine-5{40 -esters in treating angina pectoris |
US3975367A (en) * | 1971-06-08 | 1976-08-17 | The Upjohn Company | Arabinofuranosyl N4 -aminoacyl cytosine containing compounds |
DE2147094A1 (de) * | 1971-09-21 | 1973-04-05 | Robugen Gmbh | Virostatisch wirksames arzneimittel |
US4022963A (en) * | 1972-06-08 | 1977-05-10 | Deutsch Daniel Harold | Acetylation process for nucleoside compounds |
US3991045A (en) * | 1973-05-30 | 1976-11-09 | Asahi Kasei Kogyo Kabushiki Kaisha | N4 -acylarabinonucleosides |
JPS5119779A (en) * | 1974-08-12 | 1976-02-17 | Asahi Chemical Ind | N44 ashiru shichijinno seizoho |
JPS5223085A (en) * | 1975-08-12 | 1977-02-21 | Ajinomoto Co Inc | Selective n-deacylation of n4- - acylcytidine derivatives |
JPS5524150A (en) * | 1978-08-09 | 1980-02-21 | Taiho Yakuhin Kogyo Kk | Anti-malignant-tumor agent |
JPS5635196A (en) * | 1979-08-29 | 1981-04-07 | Sanyo Electric Co | Sound identification system |
JPS5791994A (en) * | 1980-11-26 | 1982-06-08 | Fuji Kagaku Kogyo Kk | 5'-o-(n-alkylcarbamoylalanyl)-5-fluorouridine and its preparation |
DE3100478A1 (de) * | 1981-01-09 | 1982-08-12 | Dr. Thilo & Co GmbH, 8021 Sauerlach | 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel |
JPS5849315A (ja) * | 1981-09-18 | 1983-03-23 | Mitsui Pharmaceut Inc | 抗腫瘍剤 |
JPS60174797A (ja) * | 1984-02-21 | 1985-09-09 | Funai Corp | Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤 |
FR2571201B1 (fr) * | 1984-10-02 | 1987-01-02 | Valeo | Procede de chauffage dans la masse d'une substance par exemple en vue d'une vulcanisation ou d'une polymerisation |
IT1178044B (it) * | 1984-10-09 | 1987-09-03 | Polifarma Spa | Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina |
DE3685315D1 (de) * | 1985-07-22 | 1992-06-17 | Teijin Ltd | Antivirus-heilmittel. |
US4762823A (en) * | 1985-10-16 | 1988-08-09 | Sloan-Kettering Institute For Cancer Research | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil |
FR2594022B1 (fr) * | 1986-02-07 | 1988-05-27 | Cousin Cie Ets A & M Freres | Articulation pour dossier de siege a grain composite. |
JPH05223085A (ja) * | 1992-02-07 | 1993-08-31 | Daikin Ind Ltd | 密閉形圧縮機 |
-
1988
- 1988-10-27 WO PCT/US1988/003823 patent/WO1989003837A1/en active IP Right Grant
- 1988-10-27 AU AU27899/89A patent/AU2789989A/en not_active Abandoned
- 1988-10-27 DE DE88909932T patent/DE3883374T2/de not_active Expired - Lifetime
- 1988-10-27 JP JP63509176A patent/JP2894610B2/ja not_active Expired - Lifetime
- 1988-10-27 AT AT88909932T patent/ATE93236T1/de not_active IP Right Cessation
- 1988-10-27 EP EP88909932A patent/EP0339075B1/de not_active Expired - Lifetime
- 1988-10-27 CA CA000581429A patent/CA1321994C/en not_active Expired - Lifetime
- 1988-10-28 IN IN755/MAS/88A patent/IN167680B/en unknown
- 1988-10-28 IL IL8820888A patent/IL88208A/en not_active IP Right Cessation
-
1989
- 1989-01-11 ZA ZA89232A patent/ZA89232B/xx unknown
-
1993
- 1993-10-25 US US08/140,475 patent/US5583117A/en not_active Expired - Lifetime
-
1994
- 1994-12-07 JP JP6303877A patent/JPH07228535A/ja active Pending
-
1997
- 1997-02-20 JP JP03673497A patent/JP3474073B2/ja not_active Expired - Lifetime
-
1998
- 1998-06-04 HK HK98104859A patent/HK1005740A1/xx not_active IP Right Cessation
-
2000
- 2000-12-13 JP JP2000379524A patent/JP2001192335A/ja not_active Withdrawn
-
2005
- 2005-12-28 JP JP2005380457A patent/JP2006137772A/ja not_active Withdrawn
-
2007
- 2007-09-07 JP JP2007233452A patent/JP2008019268A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0339075A4 (de) | 1990-04-10 |
EP0339075B1 (de) | 1993-08-18 |
WO1989003837A1 (en) | 1989-05-05 |
CA1321994C (en) | 1993-09-07 |
JPH07228535A (ja) | 1995-08-29 |
JP2006137772A (ja) | 2006-06-01 |
ZA89232B (en) | 1990-06-27 |
JP2894610B2 (ja) | 1999-05-24 |
HK1005740A1 (en) | 1999-01-22 |
JP3474073B2 (ja) | 2003-12-08 |
DE3883374T2 (de) | 1993-12-09 |
ATE93236T1 (de) | 1993-09-15 |
IL88208A0 (en) | 1989-06-30 |
JP2001192335A (ja) | 2001-07-17 |
IL88208A (en) | 1996-10-16 |
IN167680B (de) | 1990-12-08 |
US5583117A (en) | 1996-12-10 |
EP0339075A1 (de) | 1989-11-02 |
JPH02500372A (ja) | 1990-02-08 |
JPH101436A (ja) | 1998-01-06 |
JP2008019268A (ja) | 2008-01-31 |
AU2789989A (en) | 1989-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3883374D1 (de) | Acylatiertes uridin und cytidin und deren verwendungen. | |
EP0151989A3 (en) | Means for the treatment of cardiac diseases | |
ES2074867T3 (es) | Derivados de quinazolina para potenciar la actividad antitumoral. | |
PT721343E (pt) | Formulacoes farmaceuticas de factor de crescimento do tecido nervoso | |
FR2629715B1 (fr) | Derives de l'adenosine, leur procede de preparation et leur utilisation en therapeutique | |
DE3689976T2 (de) | Therapeutische Nucleoside und deren Herstellung. | |
IT1214738B (it) | Perfezionamento negli impianti di stimolazione cardiaca mediante pacemaker | |
ES2170141T3 (es) | 4-aminoderivados del acido micofenolico con actividad inmunosupresora. | |
IT1224594B (it) | Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene | |
ATE82681T1 (de) | 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen. | |
ES2002083A6 (es) | Un metodo para preparar derivados de piroglutamida | |
IT7921922A0 (it) | Procedimento per la determinazione dell'attivita' della colinesterasi e derivati della colina che vengono impiegati nel procedimento. | |
NO864514D0 (no) | Fremgangsmaate for fremstilling av thiazoloner. | |
ES2016464A6 (es) | Procedimiento para preparar derivados de 2', 5' -oligoadenilato. | |
ATE198271T1 (de) | Syndecan-stimulierung der zellulären differenzierung | |
NO165542C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-thioner. | |
DE3686472T2 (de) | Cardiotonische phenyloxazolone. | |
ES8801625A1 (es) | Procedimiento para preparar disulfuros heterociclicos | |
IT1214739B (it) | Perfezionamento negli impianti di stimolazione cardiaca mediante pacemaker | |
CA1266268C (en) | CARDIOTONIC AROYLTHIAZOLONES | |
NO870398D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive organiskeplatinakomplekser. | |
ATE68474T1 (de) | Aktive substanz in der kardiovaskulaeren therapie. | |
AR240063A1 (es) | Procedimiento para la produccion del activador del plasminogeno del tejido humano mediante el cultivo de la cepa de celulas registrada como kym-sf ifo 50135. | |
FR2621584B1 (fr) | Derives de benzothiazepine-1,5, leur preparation et leur application en therapeutique | |
NO870001D0 (no) | Farmasoeytisk baerer for nedsettelse av stroemning av terapaeutisk og kosmetisk farmakologisk aktive midler gjennom huden. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: WELLSTAT THERAPEUTICS CORP.(N.D.GES.D. STAATES CAL |